CN110770234A - 取代芳基醚类化合物、其制备方法、药用组合物及其应用 - Google Patents

取代芳基醚类化合物、其制备方法、药用组合物及其应用 Download PDF

Info

Publication number
CN110770234A
CN110770234A CN201880040666.6A CN201880040666A CN110770234A CN 110770234 A CN110770234 A CN 110770234A CN 201880040666 A CN201880040666 A CN 201880040666A CN 110770234 A CN110770234 A CN 110770234A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
group
hydrogen
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880040666.6A
Other languages
English (en)
Other versions
CN110770234B (zh
Inventor
邓贤明
张婷
康巧凤
杨燕茹
孙细欢
杨再友
李小阳
张婧芳
钟家吉
邓舟
董超
刘双
李莉
徐庆妍
胡志钰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen University
Original Assignee
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen University filed Critical Xiamen University
Publication of CN110770234A publication Critical patent/CN110770234A/zh
Application granted granted Critical
Publication of CN110770234B publication Critical patent/CN110770234B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

本发明涉及一种下面通式表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物，其制备方法、含有它的药用组合物及其在制备预防和***的药物中的用途，其中所述取代基定义见说明书。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201880040666.6A 2017-06-30 2018-06-29 取代芳基醚类化合物、其制备方法、药用组合物及其应用 Active CN110770234B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710523136.4A CN109180677A (zh) 2017-06-30 2017-06-30 取代芳基醚类化合物、其制备方法、药用组合物及其应用
CN2017105231364 2017-06-30
PCT/CN2018/093544 WO2019001556A1 (zh) 2017-06-30 2018-06-29 取代芳基醚类化合物、其制备方法、药用组合物及其应用

Publications (2)

Publication Number Publication Date
CN110770234A true CN110770234A (zh) 2020-02-07
CN110770234B CN110770234B (zh) 2022-11-29

Family

ID=64741137

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710523136.4A Pending CN109180677A (zh) 2017-06-30 2017-06-30 取代芳基醚类化合物、其制备方法、药用组合物及其应用
CN201880040666.6A Active CN110770234B (zh) 2017-06-30 2018-06-29 取代芳基醚类化合物、其制备方法、药用组合物及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710523136.4A Pending CN109180677A (zh) 2017-06-30 2017-06-30 取代芳基醚类化合物、其制备方法、药用组合物及其应用

Country Status (5)

Country Link
US (1) US11319322B2 (zh)
EP (1) EP3647313A4 (zh)
JP (2) JP2020525409A (zh)
CN (2) CN109180677A (zh)
WO (1) WO2019001556A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10030005B2 (en) 2015-11-02 2018-07-24 Blueprint Medicines Corporation Inhibitors of RET
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
WO2019195471A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
EP3833372A4 (en) 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
CN111961034A (zh) * 2019-05-20 2020-11-20 浙江同源康医药股份有限公司 用作ret激酶抑制剂的化合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007004749A1 (en) * 2005-07-05 2007-01-11 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
WO2011090738A2 (en) * 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
CN103570723A (zh) * 2012-07-27 2014-02-12 四川大学 吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
WO2015089479A1 (en) * 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2016130920A2 (en) * 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007004749A1 (en) * 2005-07-05 2007-01-11 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
WO2011090738A2 (en) * 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
CN103570723A (zh) * 2012-07-27 2014-02-12 四川大学 吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
WO2015089479A1 (en) * 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2016130920A2 (en) * 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRIAN G. LAWHORN等: "Identification of Purines and 7‑Deazapurines as Potent and Selective Type I Inhibitors of Troponin I‑Interacting Kinase (TNNI3K)", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
ENRICO PERSPICACE等: "Unexpected C-O Bond Formation in Suzuki Coupling of 4-Chlorothieno[2,3-d ]pyrimidines", 《JOURNAL OF HETEROCYCLIC CHEMISTRY》 *
LI TAN等: "Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
LING-LING YANG等: "Structure−Activity Relationship StudiesofPyrazolo[3,4‑d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently InhibitsFLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia inVitroandin Vivo", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
WEICONG WANG等: "Development of an UPLC–MS/MS method for quantification of Avitinib (AC0010) and its five metabolites in human cerebrospinal fluid: Application to a study of the blood-brain barrier penetration rate of non-small cell lung cancer patients", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 *

Also Published As

Publication number Publication date
CN110770234B (zh) 2022-11-29
US11319322B2 (en) 2022-05-03
EP3647313A4 (en) 2021-02-17
JP7439018B2 (ja) 2024-02-27
US20200123162A1 (en) 2020-04-23
WO2019001556A1 (zh) 2019-01-03
JP2021165270A (ja) 2021-10-14
CN109180677A (zh) 2019-01-11
EP3647313A1 (en) 2020-05-06
JP2020525409A (ja) 2020-08-27

Similar Documents

Publication Publication Date Title
CN110770234B (zh) 取代芳基醚类化合物、其制备方法、药用组合物及其应用
CN110997669B (zh) 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
KR102429355B1 (ko) 티에노피리미딘 화합물, 그의 제조 방법, 약학 조성물 및 용도
KR20020093086A (ko) 축합 헤테로아릴 유도체
CN107151250B (zh) 嘧啶类七元环化合物、其制备方法、药用组合物及其应用
KR20160082993A (ko) Ezh2 억제용 하이드로클로라이드 염 형태
CN113717156B (zh) Egfr抑制剂、其制备方法及用途
CN110869369A (zh) 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
CN109575045B (zh) 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
AU2013297476B2 (en) Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor
JP2022533740A (ja) メチル基及びトリフルオロメチル基を含む二置換スルファミド系選択的ｂｃｌ－２阻害剤
KR102238012B1 (ko) 브로모도메인 억제제인 카르볼린 유도체
CN113166105A (zh) 作为cdk-hdac双通路抑制剂的杂环化合物
CN110240587B (zh) 一类芳基二氟苄基醚类化合物、制备方法及用途
CN112513041B (zh) 三环化合物
CN109666022B (zh) 三氮唑衍生物及其制备方法和用途
CN111295387A (zh) 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用
CN115697996A (zh) 烯基嘧啶类化合物、其制备方法与应用
CN113166148A (zh) 作为cdk-hdac双通路抑制剂的杂环化合物
KR20210080378A (ko) 비만의 치료
WO2021254464A1 (zh) 取代喹唑啉类化合物、其制备方法、药物组合及应用
CN117999072A (zh) β肾上腺素能激动剂和其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant